Cargando…

Prediction of Overall Survival by Thymidine Kinase 1 Combined with Prostate-Specific Antigen in Men with Prostate Cancer

Thymidine kinase 1 (TK1) is an intracellular enzyme involved in DNA-precursor synthesis. Increased serum TK1 levels are used as a biomarker in various malignancies. We combined serum TK1 with PSA and evaluated its capacity to predict overall survival (OS) in 175 men with prostate cancer (PCa), detec...

Descripción completa

Detalles Bibliográficos
Autores principales: Tribukait, Bernhard, Lundgren, Per-Olof, Kjellman, Anders, Norming, Ulf, Nyman, Claes R., Jagarlmundi, Kiran, Gustafsson, Ove
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10049218/
https://www.ncbi.nlm.nih.gov/pubmed/36982234
http://dx.doi.org/10.3390/ijms24065160
_version_ 1785014401650130944
author Tribukait, Bernhard
Lundgren, Per-Olof
Kjellman, Anders
Norming, Ulf
Nyman, Claes R.
Jagarlmundi, Kiran
Gustafsson, Ove
author_facet Tribukait, Bernhard
Lundgren, Per-Olof
Kjellman, Anders
Norming, Ulf
Nyman, Claes R.
Jagarlmundi, Kiran
Gustafsson, Ove
author_sort Tribukait, Bernhard
collection PubMed
description Thymidine kinase 1 (TK1) is an intracellular enzyme involved in DNA-precursor synthesis. Increased serum TK1 levels are used as a biomarker in various malignancies. We combined serum TK1 with PSA and evaluated its capacity to predict overall survival (OS) in 175 men with prostate cancer (PCa), detected by screening in 1988–1989 (n = 52) and during follow-up (median 22.6 years) (n = 123). TK1 was measured in frozen serum, age was stratified into four groups, and dates of PCa diagnosis and dates of death were obtained from Swedish population-based registries. The median concentration of TK1 and PSA was 0.25 and 3.8 ng/ml. TK1 was an independent variable of OS. In the multivariate analysis, PSA was not statistically significant in combination with age whereas the significance remained for TK1 + PSA. Measured once, TK1 + PSA predicted a difference of up to 10 years (depending on patient subgroup) in OS at a median of 9 years before PCa diagnosis. The TK1 concentration in 193 controls without malignancies did not differ from that of the PCa patients, hence TK1 was likely not released from incidental PCa. Thus, TK1 in the blood circulation may indicate the release of TK1 from sources other than cancers, nonetheless associated with OS.
format Online
Article
Text
id pubmed-10049218
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100492182023-03-29 Prediction of Overall Survival by Thymidine Kinase 1 Combined with Prostate-Specific Antigen in Men with Prostate Cancer Tribukait, Bernhard Lundgren, Per-Olof Kjellman, Anders Norming, Ulf Nyman, Claes R. Jagarlmundi, Kiran Gustafsson, Ove Int J Mol Sci Article Thymidine kinase 1 (TK1) is an intracellular enzyme involved in DNA-precursor synthesis. Increased serum TK1 levels are used as a biomarker in various malignancies. We combined serum TK1 with PSA and evaluated its capacity to predict overall survival (OS) in 175 men with prostate cancer (PCa), detected by screening in 1988–1989 (n = 52) and during follow-up (median 22.6 years) (n = 123). TK1 was measured in frozen serum, age was stratified into four groups, and dates of PCa diagnosis and dates of death were obtained from Swedish population-based registries. The median concentration of TK1 and PSA was 0.25 and 3.8 ng/ml. TK1 was an independent variable of OS. In the multivariate analysis, PSA was not statistically significant in combination with age whereas the significance remained for TK1 + PSA. Measured once, TK1 + PSA predicted a difference of up to 10 years (depending on patient subgroup) in OS at a median of 9 years before PCa diagnosis. The TK1 concentration in 193 controls without malignancies did not differ from that of the PCa patients, hence TK1 was likely not released from incidental PCa. Thus, TK1 in the blood circulation may indicate the release of TK1 from sources other than cancers, nonetheless associated with OS. MDPI 2023-03-08 /pmc/articles/PMC10049218/ /pubmed/36982234 http://dx.doi.org/10.3390/ijms24065160 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Tribukait, Bernhard
Lundgren, Per-Olof
Kjellman, Anders
Norming, Ulf
Nyman, Claes R.
Jagarlmundi, Kiran
Gustafsson, Ove
Prediction of Overall Survival by Thymidine Kinase 1 Combined with Prostate-Specific Antigen in Men with Prostate Cancer
title Prediction of Overall Survival by Thymidine Kinase 1 Combined with Prostate-Specific Antigen in Men with Prostate Cancer
title_full Prediction of Overall Survival by Thymidine Kinase 1 Combined with Prostate-Specific Antigen in Men with Prostate Cancer
title_fullStr Prediction of Overall Survival by Thymidine Kinase 1 Combined with Prostate-Specific Antigen in Men with Prostate Cancer
title_full_unstemmed Prediction of Overall Survival by Thymidine Kinase 1 Combined with Prostate-Specific Antigen in Men with Prostate Cancer
title_short Prediction of Overall Survival by Thymidine Kinase 1 Combined with Prostate-Specific Antigen in Men with Prostate Cancer
title_sort prediction of overall survival by thymidine kinase 1 combined with prostate-specific antigen in men with prostate cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10049218/
https://www.ncbi.nlm.nih.gov/pubmed/36982234
http://dx.doi.org/10.3390/ijms24065160
work_keys_str_mv AT tribukaitbernhard predictionofoverallsurvivalbythymidinekinase1combinedwithprostatespecificantigeninmenwithprostatecancer
AT lundgrenperolof predictionofoverallsurvivalbythymidinekinase1combinedwithprostatespecificantigeninmenwithprostatecancer
AT kjellmananders predictionofoverallsurvivalbythymidinekinase1combinedwithprostatespecificantigeninmenwithprostatecancer
AT normingulf predictionofoverallsurvivalbythymidinekinase1combinedwithprostatespecificantigeninmenwithprostatecancer
AT nymanclaesr predictionofoverallsurvivalbythymidinekinase1combinedwithprostatespecificantigeninmenwithprostatecancer
AT jagarlmundikiran predictionofoverallsurvivalbythymidinekinase1combinedwithprostatespecificantigeninmenwithprostatecancer
AT gustafssonove predictionofoverallsurvivalbythymidinekinase1combinedwithprostatespecificantigeninmenwithprostatecancer